Virbagen Puppy 2b
Country: Italy
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
29-08-2012
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
canine parvovirus 5675 CCID50
Available from:
Virbac S.A.
ATC code:
QI07AD01
Pharmaceutical form:
Suspension for injection
Therapeutic group:
Canine parvovirus vaccine
Therapeutic area:
Dogs Non Food
Authorization date:
2008-03-26
Summary of Product characteristics
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CANIGEN PUPPY 2b
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains
ACTIVE SUBSTANCE:
Live attenuated canine Parvovirus 2b Strain CPV39: 10
5.6
to 10
7,5
CCID
50
*
* Cell culture infectious dose.
EXIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Colourless suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog (puppy)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of dogs against canine parvovirosis, to reduce virus excretion, to prevent mortality
and typical signs (enteric form) from the age of 5 weeks.
The onset of protection occurs two weeks after vaccination. The duration of protection has been
demonstrated until the age of 11 weeks.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The vaccinal strain can spread. It has been demonstrated that this spread did not cause adverse effects on
pregnant or lactating females or cats.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The vaccine should be administered in accordance with the usual aseptic conditions for vaccination.
Animals have to be treated for intestinal endoparasites prior to vaccination. Vaccinate only healthy puppies.
In the case of high levels of maternal derived antibodies (>1/80) the seroconversion rate is reduced from
94% to 42%.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT
Read the complete document
